Jeffrey La Rosa
Stock Analyst at Leerink Partners
(0.02)
# 4,666
Out of 5,182 analysts
5
Total ratings
20%
Success rate
-41.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey La Rosa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNTI Senti Biosciences | Initiates: Outperform | $6 | $0.87 | +593.48% | 1 | Nov 21, 2025 | |
| JANX Janux Therapeutics | Maintains: Outperform | $79 → $91 | $14.53 | +526.29% | 2 | Dec 3, 2024 | |
| PYXS Pyxis Oncology | Initiates: Outperform | $12 | $1.61 | +645.34% | 1 | Jan 23, 2024 | |
| MRK Merck & Co. | Maintains: Outperform | $110 → $112 | $122.68 | -8.71% | 1 | Oct 28, 2022 |
Senti Biosciences
Nov 21, 2025
Initiates: Outperform
Price Target: $6
Current: $0.87
Upside: +593.48%
Janux Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $79 → $91
Current: $14.53
Upside: +526.29%
Pyxis Oncology
Jan 23, 2024
Initiates: Outperform
Price Target: $12
Current: $1.61
Upside: +645.34%
Merck & Co.
Oct 28, 2022
Maintains: Outperform
Price Target: $110 → $112
Current: $122.68
Upside: -8.71%